Yahoo Science News feed latest items
“Day One” isn’t just for Amazon anymore: Billionaire Jeff Bezos says that first-day feeling of being fired up about a business venture applies to Blue Origin and the commercial space industry as well. Bezos, the founder of Amazon as well as his privately held Blue Origin space venture, made the comment in a newly published interview with Via Satellite’s Mark Holmes, which was conducted during the magazine’s Satellite 2018 conference in March. Here’s how Bezos summarized the message he wanted to get across: “I would be super optimistic about the future. The message would be that I think this is… Read More
Launch abort? Trump tries to get his 'Space Force' off the ground, but not everyone is on board
President Trump wants a Space Force, and some legislators and analysts believe the military needs a new branch devoted to warfare beyond the atmosphere, but there is opposition within the administration itself.
Tom's Guide tested all of the major smartphones on the market by dropping them over the course of four rounds from 4 feet and 6 feet onto wood and concrete - and even into a toilet - to see which handset is the toughest. Editor & Chief Mark Spoonauer is here to share some of the results.
In the wild and wooly world of quantum computing, everything must be taken with a grain of salt. For example, Microsoft’s (MSFT) comment that it will have a production-ready quantum computer in five years’ time—a comment made to this blog in February—is met with a pleasant smile and something of a shrug by James Clarke, the director of quantum hardware for Intel (INTC).
Next month, however, an international team of scientists led by Neil Gemmell from the University of Otago, New Zealand, will conduct an investigation into the waters of the famous loch which could help to settle the mystery once and for all. The scientists will sample the water using so-called environmental DNA (eDNA), which will enable them to identify tiny remnants of genetic material left behind by any life in the loch.
A trail-blazer in internet technology, cyber-savvy Estonia is rolling out a high-tech DNA database holding the genetic details of over 150,000 residents to improve the prevention, diagnosis and treatment of chronic disease. The database is intended to find and map genetic variations, and will build on existing genetic records for over 52,000 Estonians collected since the centre opened in 2001.
The most common cause of incurable blindness could be stopped early after scientists discovered the genetic blueprint which predicts who is in danger of developing the condition. Around 480,000 people suffer from glaucoma in England which starts with a loss of peripheral vision and gradually spreads. It is thought to be caused by a build-up of pressure in the eye which compresses the optic nerve. But in the early stages, symptoms are often absent and many people are unaware they have the condition until the damage is already one. Now King’s College London,Moorfields Eye Hospital and Harvard Medical School have discovered the 133 genetic variants that put people at risk of developing the condition. It suggests that a test could created that could find out who is susceptible as early as childhood, so treatment could be given before any damage occurs. Lead author, Dr Pirro Hysi from King’s College, said: ‘Knowing someone’s genetic risk profile might allow us to predict what risk of glaucoma he or she carries so that in the future we can focus scarce health care resources on those most at risk.” Most people do not realise they are suffering from glaucoma until the damage has already been done Credit: Picasa Co-author Dr Anthony Khawaja from the NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, said: “With this new knowledge, we are now more able to predict the risk of an individual developing glaucoma. “The predictive genetic markers could be measured as early as birth, even though glaucoma develops later in adulthood. ‘These results help us to better understand the previously unknown mechanisms that cause this damaging disease. “By understanding how glaucoma develops we can, in time, get ahead of the curve of the condition and support both those living with the disease and those who may develop it.” To find out which genes were responsible, scientists studied 140,000 people drawn from the UK Biobank and EPIC-Norfolk. Eye pressure readings were taken which were compared with a DNA analysis of each patient to assess how likely it was that they would develop the condition. By comparing the pressure test results with a genetic analysis of the many common, small variations in DNA that contribute a tiny amount to overall eye pressure, the team was able to identify 133 genetic variants in the DNA of those who had high pressure readings, and so were at highest risk of developing the condition. The genetic variations were able to predict whether someone might develop glaucoma with 75 per cent accuracy. Dr. Janey Wiggs, co-author from Massachusetts Eye and Ear and Harvard Medical School said: “This study demonstrates the enormous power of large datasets allowing detection of these important genetic risk factors. “Glaucoma remains the leading cause of incurable blindness in the world, but the hope is that this important piece of research could help millions by leading to faster and more accurate diagnoses in the future.” The research was published in Nature Genetics.
Britain's prime minister challenged scientists on Monday to help diagnose cancer earlier and create zero-emission cars, trying to reboot an industrial strategy all but eclipsed by Brexit, while acknowledging Britain's reliance on foreign scientists. Theresa May, who is struggling to unite her top ministers over plans to leave the European Union, wants to broaden her agenda to show she is more than a leader charged with overseeing Britain's messy divorce with the bloc. In a speech in northern England, May pressed home her desire for Britain to be a leader in scientific research even after it leaves the bloc in March next year.
NIH Funding Opportunities
- Request for Information (RFI): Strategies for Enhancing Postdoctoral Career Transitions to Promote Faculty Diversity
- Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R41/R42 - Clinical Trial Optional)
- Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R43/R44 - Clinical Trial Optional)
- Notice for the All of Us Research Program Genome Centers (OT2) Funding Announcement and Informational Webinar
- Biomarkers Discovery In Parkinsonism (U01 Clinical Trial Optional)